| Product Description | IST5-002, a potent Stat5a/b inhibitor, selectively inhibits transcriptional activity of Stat5a/b ( IC 50 s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) cells. IST5-002 can be used in the research of prostate cancer and chronic myeloid leukemia (CML) In Vitro IST5-002 (1.5-25 μM, 2 h) inhibits transcriptional activity of Stat5a and Stat5b in a dose-dependent manner. IST5-002 (0-40 μM, 3 h) inhibits Bcr-Abl-induced Stat5a/b phosphorylation in K562 cells. IST5-002 (5-100 μM, 2 h) inhibits Stat5a/b phosphorylation in T47D cells, and inhibits dimerization in PC-3 cells. IST5-002 (5-100 μM, 2 h) suppresses Stat5 nuclear translocation in PC-3 cells, and inhibits DNA binding of Stat5 target genes and COS-7 cells. IST5-002 (2-50 μM, 48 h) reduces expression of Stat5a/b target genes (Bcl-xL and cyclin D1) in CWR22Rv1 and LNCaP cells. IST5-002 (3.1-50 μM, 72 h) inhibits cell growth through induction of apoptosis in human prostate cancer cells. IST5-002 (25-100 μM, 7 days) induces epithelial cell death in patient-derived prostate cancers ex vivo in organ explant cultures. IST5-002 (5 μM, 24-72h) inhibits Stat5a/b phosphorylation and induces apoptosis of Imatinib (HY-15463)-sensitive and -resistant CML cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: CWR22Rv1, LNCaP, and DU145 cells Concentration: 3.1, 6.3, 12.5, 25, 50 μM Incubation Time: 72 h Result: Decreased viable cells by 50% to 80% at 12.5 μM. Cell Cycle AnalysisCell Line: LNCaP and CWR22Rv1 cells Concentration: 6, 12, 25 μM Incubation Time: 72 h Result: Increased the fraction of dead cells (sub-G1) and decreased the fraction of living cells (G2–M). Western Blot AnalysisCell Line: Bcr-Abl–positive K562 cells Concentration: 0, 1, 5, 10, 20, 40 μM Incubation Time: 3 h Result: Inhibited Bcr-Abl-induced Stat5a/b phosphorylation at 5 μM, without affecting Bcr-Abl tyrosine phosphorylation levels. ImmunofluorescenceCell Line: PC-3 cells Concentration: 5, 10, 15. 20, 40 μM Incubation Time: 2 h Result: Inhibited Prl (Prolactin)-induced nuclear translocation of Stat5. In Vivo RORγt inverse agonist 29 (intraperitoneal injection, 25-100 mg/kg, daily for 10 days) inhibits tumor growth in prostate cancer xenograft model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Prostate cancer (CWR22Rv1) xenograft model Dosage: 25, 50, and 100 mg/kg Administration: Intraperitoneal injection, daily for 10 days Result: Induced massive loss of viable tumor cells and dead rounded cells accumulation. Induced cell death through apoptosis (shown by fragmented DNA in tumor sections). Decreased nuclear Stat5a/b content by 60%, 78%, and 90% at 25, 50, and 100 mg/kg, respectively. Form:Solid IC50& Target:STAT5a 1.5 μM (IC 50 ) STAT5b 3.5 μM (IC 50 ) |
|---|
